Congresses and Publications | In Develoment | Savara Inc.

View publications or poster/presentations from medical congresses.

For the years when there were no publications, posters and presentations, the section will be empty.

Molgramostim Reduces Surfactant Background Burden and Number of Whole Lung Lavage Procedures in Patients with Autoimmune Pulmonary Alveolar Proteinosis (PAP): Results from the IMPALA-2 Phase 3 Clinical Trial (PDF)

Wang, Tisha, et al ATS (2025)

The Effects of Molgramostim on Respiratory Health-Related Quality of Life and Patient-Reported Outcomes in Patients with Autoimmune Pulmonary Alveolar Proteinosis (PAP) (PDF)

Ataya, Ali, et al ATS (2025)

Encore Presentation: Inhaled Molgramostim for the Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP) - Results from the IMPALA-2 Phase 3 Clinical Trial (PDF)

Inoue, Yoshikazu, et al JRS (2025)

Encore Presentation: Inhaled Molgramostim Improves Pulmonary Gas Exchange, Quality of Life, and Exercise Capacity in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (PDF)

Bonello F, et al, DGP (2025)

Long-Term Outcomes in Five Patients with Autoimmune Pulmonary Alveolar Proteinosis Treated with Molgramostim Inhalation Solution (PDF)

Montaño C, et al (ERJ 2025)

Inhaled Molgramostim Improves Pulmonary Gas Exchange and Respiratory Health-Related Quality of Life in Patients with Autoimmune Pulmonary Alveolar Proteinosis: Results from IMPALA-2 (PDF)

McCarthy, C. et al (BTS) (2024)

A Patient Journey Map for People Living with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (PDF)

Sathyanarayanan S, et al, CHEST (2024)

Inhaled Molgramostim Therapy for the Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP): A Plain Language Summary of the IMPALA Trial (PDF)

Trapnell BC. (2024) Hosp Pract; 52:1–4

Inhaled Molgramostim Improves Pulmonary Gas Exchange and Respiratory Health-Related Quality of Life (HRQoL) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP): Results from Phase 3 IMPALA-2 Clinical Trial (PDF)

Trapnell B, et al, ERS (2024)

Healthcare Burden of Pulmonary Alveolar Proteinosis (PAP) (PDF)

Lee E, et al, ATS (2024)

Novel Laboratory Test for the Detection of GM-CSF Antibodies to Aid in the Diagnosis of Individuals at-risk for Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (PDF)

Kim J, et al, ATS (2024)

IMPALA-2: Choice of DLco as a Primary Endpoint in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (PDF)

Trapnell B, et al, ERS (2022)

Safety and Tolerability of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (PDF)

Bonella F, et al, ERS (2022)

IMPALA: Efficacy Measures in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Who Required Whole Lung Lavage (PDF)

Chowdhury B, et al, ERS (2022)

Inhaled Molgramostim Therapy in Autoimmune Pulmonary Alveolar Proteinosis ()

Trapnell B, et al (2020). N Engl J Med; 383:1635-1644.

Patient Education: Pulmonary Alveolar Proteinosis (PAP) ()

Riley L, et al (2019). Am J Respir Crit Care Med.; 200(8):16-17.

Safety and Efficacy of Inhaled GM-CSF (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis—the IMPALA Trial—Baseline Data and Blinded Treatment Period Results (PDF)

Trapnell B, et al. ERS (2019).

First Randomized, Placebo-Controlled Trial of Inhaled rhGM-CSF in aPAP Patients (PDF)

Bonella F, et al (2016).

Results of Phase 1 Clinical Trial for Molgramostim (PDF)

Tarnow I, et al, ATS (2016).

Savara's news center

View Savara's press releases